Nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2025-05-09 DOI:10.1080/14796678.2025.2503640

Ayesha Shaukat, Muhammad Ahmed Zahoor, Laiba Shakeel, Muniba Ijaz, Zobia Ahmad, Wajiha Zehra, Zaigham Ali, Muhammad Umar Mian, Rabbia Munsab, Zainab Awan, Ismat Fatima, Simran Suleman Panjwani, Muhammad Taha, Juvairia Yousuf, Muhammad Hasanain, Muhammad Umair Anjum, Muhammad Omar Larik

{"title":"Nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis.","authors":"Ayesha Shaukat, Muhammad Ahmed Zahoor, Laiba Shakeel, Muniba Ijaz, Zobia Ahmad, Wajiha Zehra, Zaigham Ali, Muhammad Umar Mian, Rabbia Munsab, Zainab Awan, Ismat Fatima, Simran Suleman Panjwani, Muhammad Taha, Juvairia Yousuf, Muhammad Hasanain, Muhammad Umair Anjum, Muhammad Omar Larik","doi":"10.1080/14796678.2025.2503640","DOIUrl":null,"url":null,"abstract":"Introduction: Contrast-induced nephropathy (CIN) is a feared complication of angiographic procedures, resulting in a sudden decline in renal function.Methods: PubMed, ScienceDirect, and Google Scholar were searched for potentially relevant articles from inception till August 2024. The meta-analysis was conducted using RevMan 5.4 with risk ratios (RR), mean differences (MD), and 95% confidence intervals (95% CI) computed.Results: Ultimately, 13 studies were incorporated in the analysis. Nicorandil portrayed a significant protective effect against CIN (RR: 0.42; 95% CI: 0.33-0.54; p < 0.00001). Subgroup analysis revealed the superiority of the oral administration (RR: 0.38; 95% CI: 0.28-0.50; p < 0.00001). Nicorandil was also effective in reducing CIN in renal dysfunction patients (RR: 0.40; 95% CI: 0.27-0.59; p < 0.00001). Blood urea nitrogen (BUN) and cystatin-C 48-hours post-procedure (MD: -0.42; 95% CI: -0.53--0.30; p < 0.00001 and MD: -0.27; 95% CI: -0.51--0.02; p = 0.03, respectively) were superior in the nicorandil cohort. Serum creatinine was significantly lower in patients receiving nicorandil at 24- and 72-hour intervals (MD: -3.18, MD: -4.26, and MD: -3.75, respectively). There were no increased risks of adverse events in the nicorandil cohort.Conclusion: Nicorandil has promising efficacy and safety in reducing the risk of CIN. However, further trials are necessary in order to validate our conclusions.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-11"},"PeriodicalIF":1.6000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2503640","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Contrast-induced nephropathy (CIN) is a feared complication of angiographic procedures, resulting in a sudden decline in renal function.

Methods: PubMed, ScienceDirect, and Google Scholar were searched for potentially relevant articles from inception till August 2024. The meta-analysis was conducted using RevMan 5.4 with risk ratios (RR), mean differences (MD), and 95% confidence intervals (95% CI) computed.

Results: Ultimately, 13 studies were incorporated in the analysis. Nicorandil portrayed a significant protective effect against CIN (RR: 0.42; 95% CI: 0.33-0.54; p < 0.00001). Subgroup analysis revealed the superiority of the oral administration (RR: 0.38; 95% CI: 0.28-0.50; p < 0.00001). Nicorandil was also effective in reducing CIN in renal dysfunction patients (RR: 0.40; 95% CI: 0.27-0.59; p < 0.00001). Blood urea nitrogen (BUN) and cystatin-C 48-hours post-procedure (MD: -0.42; 95% CI: -0.53--0.30; p < 0.00001 and MD: -0.27; 95% CI: -0.51--0.02; p = 0.03, respectively) were superior in the nicorandil cohort. Serum creatinine was significantly lower in patients receiving nicorandil at 24- and 72-hour intervals (MD: -3.18, MD: -4.26, and MD: -3.75, respectively). There were no increased risks of adverse events in the nicorandil cohort.

Conclusion: Nicorandil has promising efficacy and safety in reducing the risk of CIN. However, further trials are necessary in order to validate our conclusions.

查看原文本刊更多论文

尼可地尔预防冠脉造影患者造影剂肾病：一项荟萃分析

造影剂肾病（CIN）是血管造影手术中一种令人恐惧的并发症，可导致肾功能突然下降。方法：检索PubMed、ScienceDirect和谷歌Scholar从建校到2024年8月的潜在相关文章。采用RevMan 5.4进行meta分析，计算风险比（RR）、平均差异（MD）和95%置信区间（95% CI）。结果：最终，13项研究被纳入分析。尼可地尔对CIN有显著的保护作用(RR: 0.42；95% ci: 0.33-0.54；P P P P P = 0.03)在尼可地尔组中更优。服用尼可地尔的患者在24小时和72小时的间隔内血清肌酐显著降低（MD: -3.18, MD: -4.26, MD: -3.75）。在尼可地尔组中，不良事件的风险没有增加。结论：尼可地尔在降低CIN风险方面具有良好的疗效和安全性。然而，为了验证我们的结论，还需要进一步的试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.